Live
FierceBiotechChutes & Ladders—Eric Topol boards Flagship as advisorFierceBiotechBehind the curtain: What Xaira is building after its $1B fundraiseFierceBiotechIntuitive recalls surgical stapler reloads following patient deathAgilentAgilent Brings Expanded PD-L1 Testing and Digital Pathology Workflows to USCAP 2026 - Clinical Lab ProductsBioPharma DiveRoche stops work on experimental SMA drugEndpoints NewsSarepta to ask FDA for full approval of exon skipping drugs; Rhythm's label expansion in rare form of obesityEndpoints NewsChina-rooted AI biotech Earendil Labs raises $787M ahead of possible IPOEndpoints NewsUK’s NICE revisits Lilly, Eisai Alzheimer's drugs under new pricing thresholdBioPharma DiveNovartis pays $2B to land a startup’s breast cancer drugAgilentAgilent Debuts Future of the Automated Laboratory at Korea Lab 2026 - marketscreener.comPharmaVoiceGilead could potentially end HIV. But will it be able to?BioWorldTreeline Biosciences reports TEAD degraders
Endpoints News Mar 20, 2026

Sarepta to ask FDA for full approval of exon skipping drugs; Rhythm's label expansion in rare form of obesity

Sarepta to ask FDA for full approval of exon skipping drugs; Rhythm's label expansion in rare form of obesity

Original
Body unavailable. Use the original source.

Directory

59 All